News Brief
Remdesivir
Union Minister of State for Chemicals and Fertilisers Mansukh Mandaviya on Tuesday (5 May) announced that the production of the antiviral drug Remdesivir in the country has increased three times from 37 lakh vials to 1.05 crore vials in less than a month.
It should be noted that the demand for the antiviral drug Remdesivir, which is used in the treatment of Covid-19 patients, has been increasing in the country as the fresh Coronavirus infections are on a rise.
"The production of remdesivir is being increased at a rapid pace in the country. In just a few days, India has achieved three times the production capacity of Remedesvir and will soon be able to meet the growing demand," Mandaviya said in a tweet.
The Remdesivir production has gone up from 37 lakh on 12 April 2021 to 1.05 crore vials per month on 4 May 2021, the Ministry of Chemicals and Fertilisers said in a statement.
In view of the increase in demand, the number of plants producing Remdesivir has also gone up from 20 on 12 April to 57 on 4 May, the minister said.
In view of the increase in demand, the number of plants producing Remdesivir has also gone up from 20 to 57 as on 4 May, he added.
Support Swarajya's 50 Ground Reports Project & Sponsor A Story
Every general election Swarajya does a 50 ground reports project.
Aimed only at serious readers and those who appreciate the nuances of political undercurrents, the project provides a sense of India's electoral landscape. As you know, these reports are produced after considerable investment of travel, time and effort on the ground.
This time too we've kicked off the project in style and have covered over 30 constituencies already. If you're someone who appreciates such work and have enjoyed our coverage please consider sponsoring a ground report for just Rs 2999 to Rs 19,999 - it goes a long way in helping us produce more quality reportage.
You can also back this project by becoming a subscriber for as little as Rs 999 - so do click on this links and choose a plan that suits you and back us.
Click below to contribute.
Latest